Daptomycin use in pediatric patients

Durand, Cheryl; Brueckner, A.; Sampadian, Chelsea; Willett, Kristine C.; Belliveau, Paul P.

doi:10.2146/ajhp130601

Cited by 13 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Methicillin-resistant S. aureus (MRSA) has emerged as a common pathogen in both healthcare and community-acquired infections [ 7 , 8 ]. Community-acquired MRSA has been found to be particularly responsible for causing IE in patients with human immunodeficiency virus [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin® Outcomes Registry and Experience (EU-CORE)

et al. 2015

View full text Add to dashboard Cite

IntroductionThe European Cubicin® Outcomes Registry and Experience (EU-CORESM) was a retrospective, non-interventional, multicenter study which evaluated the safety and effectiveness of daptomycin therapy in patients with Gram-positive infections including infective endocarditis (IE).MethodsData from the EU-CORE registry were collected for patients with IE who had received at least one dose of daptomycin between January 2006 and April 2012, across 18 countries in Europe (12), Latin America (5) and Asia (1). Clinical outcomes were assessed as success (cured or improved), failure or non-evaluable. Adverse events (AEs) were recorded during treatment and for up to 30 days post-treatment; follow-up data were collected for 2 years.ResultsOf 6075 patients included in the EU-CORE registry, 610 were diagnosed with IE as primary infection; 149 (24.4%) right-sided IE (RIE), 414 (67.9%) left-sided IE (LIE), and 47 (7.7%) with both right- and left-sided IE (BRLIE). Overall clinical success was achieved in 80.0% of patients (RIE 88.6%, LIE 76.6% and BRLIE 82.9%). Success rates for methicillin-resistant Staphylococcus aureus (MRSA) infections were 90.9%, 71.7% and 66.6% in patients with RIE, LIE and BRLIE, respectively. The overall sustained clinical success rate in patients followed for up to 2 years was 86.7% (RIE 93.5%, LIE 88.3% and BRLIE 77.8%). AEs deemed possibly related to daptomycin in the investigator’s opinion were reported in 2 (1.3%) RIE, 18 (4.3%) LIE and 1 (2.1%) BRLIE patients. There were 11 (1.8%) patients (2 with RIE, 8 with LIE and 1 with BRLIE) with AEs of creatine phosphokinase elevation reported as possibly related to daptomycin.ConclusionData from this real-world clinical setting showed that daptomycin was well tolerated and effective for the treatment of LIE and BRLIE in addition to RIE caused by Gram-positive bacteria, including MRSA. Two-year follow-up data showed that a high proportion of patients had a sustained response.Electronic supplementary materialThe online version of this article (doi:10.1007/s40121-015-0075-9) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin® Outcomes Registry and Experience (EU-CORE)

et al. 2015

View full text Add to dashboard Cite

show abstract

“…2 Limited pharmacokinetic studies have manifested faster daptomycin clearance in children and it seems to have a shorter half-life in children aged 2-6 when compared to children aged 12-17. 10 Higher doses may be required in younger patients and the administration of 15 mg/kg/12 h was reported as a maximum dose in the literature in an infant. 2,8 Our patient was treated at a dose of 8 mg/kg/ Serum CPK levels were in normal limits during the treatment.…”

Section: Case Reportmentioning

confidence: 99%

Vancomycin-resistant Enterococcus bacteremia in a child with acute myeloid leukemia: Successful treatment with daptomycin

et al. 2016

View full text Add to dashboard Cite

Multiple-drug-resistant enterococcal infections can be a serious problem in pediatric patients particularly concomitance with severe underlying diseases and lead to significant morbidity and mortality. The treatment options in children are limited compared with adults. We report a 3-year old-boy with acute myeloid leukemia (AML)-M7 and vancomycin-resistant enterococcus bacteremia successfully treated with daptomycin. Daptomycin may be an alternative therapy for VRE infections in children; more studies are needed for extended usage. BACKGROUNDVancomycin-resistant Enterococcus (VRE) infections is a global clinical problem at the hospital settings and can cause infective endocarditis, catheter-related bloodstream infections, urinary tract infections and bacteremia of unknown source. VRE bacteremia is a major cause of nosocomial infections with a significant morbidity and mortality especially in children with underlying severe chronic diseases.

show abstract

“…However, production of toxic compounds by some of these bacteria raises concerns about the safety of these isolates in food production (Camargo et al., ; Choi & Woo, ; Franz et al., ). Additionally, several studies reported that enterococci can transfer resistance to even more virulent bacteria, such as Staphylococcus aureus (Bellanger et al., ; Durand, Brueckner, Sampadian, Willett, & Belliveau, ). Hence, the ability of enterococci to act as reservoirs of antibiotic resistance genes within the food chain poses an important food safety risk (Delpech et al., ; Gousia, Economou, Bozidis, & Papadopoulou, ; Jahan, Krause, & Holley, ; Pesavento, Calonico, Ducci, Magnanini, & Lo Nostro, ; Stensland et al., ).…”

Section: Introductionmentioning

confidence: 99%

Genomic insights into the pathogenicity and environmental adaptability of Enterococcus hirae R17 isolated from pork offered for retail sale

Peng

Wang

et al. 2017

MicrobiologyOpen

View full text Add to dashboard Cite

Genetic information about Enterococcus hirae is limited, a feature that has compromised our understanding of these clinically challenging bacteria. In this study, comparative analysis was performed of E. hirae R17, a daptomycin‐resistant strain isolated from pork purchased from a retail market in Beijing, China, and three other enterococcal genomes (Enterococcus faecium DO, Enterococcus faecalis V583, and E. hirae ATCC ™9790). Some 1,412 genes were identified that represented the core genome together with an additional 139 genes that were specific to E. hirae R17. The functions of these R17 strain‐specific coding sequences relate to the COGs categories of carbohydrate transport and metabolism and transcription, a finding that suggests the carbohydrate utilization capacity of E. hirae R17 may be more extensive when compared with the other three bacterial species (spp.). Analysis of genomic islands and virulence genes highlighted the potential that horizontal gene transfer played as a contributor of variations in pathogenicity in this isolate. Drug‐resistance gene prediction and antibiotic susceptibility testing indicated E. hirae R17 was resistant to several antimicrobial compounds, including bacitracin, ciprofloxacin, daptomycin, erythromycin, and tetracycline, thereby limiting chemotherapeutic treatment options. Further, tolerance to biocides and metals may confer a phenotype that facilitates the survival and adaptation of this isolate against food preservatives, disinfectants, and antibacterial coatings. The genomic plasticity, mediated by IS elements, transposases, and tandem repeats, identified in the E. hirae R17 genome may support adaptation to new environmental niches, such as those that are found in hospitalized patients. A predicted transmissible plasmid, pRZ1, was found to carry several antimicrobial determinants, along with some predicted pathogenic genes. These data supported the previously determined phenotype confirming that the foodborne E. hirae R17 is a multidrug‐resistant pathogenic bacterium with evident genome plasticity and environmental adaptability.

show abstract

Daptomycin use in pediatric patients

Cited by 13 publications

References 14 publications

Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin® Outcomes Registry and Experience (EU-CORE)

Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin® Outcomes Registry and Experience (EU-CORE)

Vancomycin-resistant Enterococcus bacteremia in a child with acute myeloid leukemia: Successful treatment with daptomycin

Genomic insights into the pathogenicity and environmental adaptability of Enterococcus hirae R17 isolated from pork offered for retail sale

Contact Info

Product

Resources

About